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Abstract
Background
Data from discovery proteomic and phosphoproteomic experiments typically include
missing values that correspond to proteins that have not been identified in the analyzed
sample. Replacing the missing values with random numbers, a process known as
“imputation”, avoids apparent infinite fold-change values. However, the procedure comes
at a cost: Imputing a large number of missing values has the potential to significantly
impact the results of the subsequent differential expression analysis.
Results
We propose a method that identifies differentially expressed proteins by ranking their
observed changes with respect to the changes observed for other proteins. Missing values
are taken into account by this method directly, without the need to impute them. We
illustrate the performance of the new method on two distinct datasets and show that it is
robust to missing values and, at the same time, provides results that are otherwise similar
to those obtained with edgeR which is a state-of-art differential expression analysis
method.
Conclusion
The new method for the differential expression analysis of proteomic data is available as
an easy to use Python package.
Keywords
Proteomics; Differential expression analysis; Ranking; Imputation; Significance
Background
The recent availability of high-resolution omic measurements has called for the creation
of statistical methods and tools to analyze the resulting data [1–4]. Proteomics, a
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large-scale analysis of proteins in biomaterials such as cells or plasma, in particular, can
help elucidate molecular mechanisms of disease, aging, and effects of the environment [5].
Expression proteomics, quantitative study of protein expression between samples that
differ by some variable, is used to identify novel proteins in signal transduction or disease-
specific proteins [6, 7]. The application of proteomic technologies to clinical specimens
has the potential to revolutionize the treatment of many diseases: From biomarker
discovery and validation to personalized therapies, proteomic techniques allow a greater
understanding of the dynamic processes involved in disease, increasing the power of
prediction, diagnosis, and prognosis [8–11]. Detailed measurements of protein levels allow
for characterizing protein modifications and identifying the targets of drugs [12]. The
quantitative study of protein expression between samples that differ by some variable
is known as expression proteomics. In this approach, protein expression of the entire
proteome or its subproteomes between samples can be compared. This can help identify
novel proteins in signal transduction or identify disease-specific proteins.
However, data from proteomic and phosphoproteomic experiments are not error-free.
Of various measurement errors, missing values are particularly severe. They arise when
signals from some proteins are not detected by the instrument. Due to the technical setup
of measurements, proteomic data often contain a considerable fraction of missing (zero)
values. To avoid mathematical difficulties (such as infinite or very large logarithmic fold
changes in pairwise comparisons involving a missing value), missing values are typically
removed by a process which is referred to as imputation: All missing values are replaced
by samples from a given distribution [7]. Besides the need to choose the distribution’s
parameters, the often-ignored drawback of value imputation is that it has the potential
to distort the analysis results. We use two real datasets to show that imputation indeed
significantly alters the analysis results. We propose a method for differential expression
analysis of proteomic data where missing values can be taken into account naturally,
without the need to replace them by random numbers.
To demonstrate that the new method performs well, we use transcriptomic data
where missing values do not pose a problem. Standard methods for differential expression
analysis, such as the edgeR package [2] which performs well in many cases [13], can
be therefore used to produce reliable results on transcriptomic data. We use the thus-
obtained results as a benchmark with which we compare the results produced by the
newly proposed method. Subsequently, we introduce artificial missing values in the
analyzed data to demonstrate that the new method is significantly more robust to the
presence of missing values than edgeR. We conclude by analyzing phosphoproteomic
data where problematic missing values occur naturally. An implementation of the new
method in Python is available at https://github.com/8medom/ProtRank (see How to
use the ProtRank package for a brief usage description).
Results
Missing values in proteomic data and their impact
The simplest way how to deal with missing values is to ignore them and analyze only
the proteins that have no missing values at all. This is problematic for two reasons.
First, proteomic data typically involve a large fraction of missing values and the proteins
that have no missing values can be thus correspondingly scarce. In the case of the
phosphoproteomic data analyzed later (see Description of the phosphoproteomic data for
details), for example, the overall fraction of missing values is 43.6% and only 37.9% of
all proteins have no missing values. The data on the remaining 62.1% of proteins would
be wasted in this case. Second, the missing values can contain important information:
A protein can be absent in the results not due to a measurement error but because of
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Fig 1. The distribution of positive counts in pairwise comparisons where
the other count is zero. We compare here transcriptomic and phosphoproteomic
data. To make the two datasets directly comparable, the positive counts are scaled by
the datasets’ respective median counts.
actual biological processes—application of an inhibitive treatment, for example. For this
reason, we need an approach that can analyze proteomic data where missing values are
still present.
A comparison between expression values in different samples is usually based on
logarithmic fold change values. Denoting the counts of gene g in samples 1 and 2 as
ng,1 and ng,2, respectively, the logarithmic fold change of sample 2 compared to sample
1 is defined as xg(1→ 2) := log2 ng,2/ng,1 (we use “gene count” as a generic term for
data from a proteomic/phosphoproteomic/transcriptomic measurement). To avoid an
undefined expression when either of the counts is zero, a small prior count n0 is usually
added to both of them, so that the logarithmic fold change becomes
xg(1→ 2) := log2
ng,2 + n0
ng,1 + n0
. (1)
We use n0 = 1 through the paper. However, this approach is not effective in proteomic
data where missing values appear also in comparisons where the other count is very large.
The resulting logarithmic fold change, though not infinite, is then still large and has the
potential to distort the statistical analysis of the data. The different patterns of missing
values in various datasets are illustrated by Fig 1 which shows the distributions of positive
values in pairwise comparisons involving zero and a positive count. The distributions
are shown for two different datasets: A transcriptomic dataset analyzed in [14] and
a phosphoproteomic dataset analyzed in [Koch et al, manuscript in preparation] (see
Description of the transcriptomic data and Description of the phosphoproteomic data
for the datasets’ descriptions). To allow for easy comparison, the counts are scaled
by the dataset’s median in both cases. While in the transcriptomic data, zeros occur
in comparisons with small counts (and hence bulk of the shown distribution is close
to zero), the phosphoproteomic data are very different and contain a large number of
proteins whose count changes from a large value (larger than, for example, the median
count) to zero or vice versa. Missing values involved in such comparisons are referred to
irregular zeros from now on. Another way of looking at irregular zeros is provided by
the following probabilistic statement: For counts greater than the dataset’s median in
the phosphoproteomic dataset, the probability that the other value in the comparison is
zero is 0.11. The same probability is 4.6 · 10−5 in the transcriptomic dataset.
When irregular zeros are present in the data, n0 necessary to shrink the logarithmic
fold change values computed with Eq. (1) is prohibitively large (of the order of the
median count): It would significantly shrink also the logarithmic fold change values in
comparisons without irregular zeros, and the differential expression analysis would be
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Fig 2. The impact of imputation on differential expression analysis. The
fraction of the significant genes identified by edgeR in the original transcriptomic data
that are lost when the data are analyzed by edgeR after imputing missing values with
various shift and scale parameters. Significance was evaluated with edgeR using the
false discovery rate (FDR) threshold of 0.20. Results are averaged over 30 imputation
realizations.
thus still distorted towards comparisons involving irregular zeros. In summary, setting
n0 > 0 is useful to shrink the logarithmic fold changes for low counts towards zero, but
n0 itself cannot solve the problem of irregular zeros.
Methods aiming specifically at the analysis of proteomic data acknowledge the problem
of missing values and deal with it by various “imputation” techniques. For example, the
authors of the Perseus computational platform for proteomic data [7] suggest to replace
the missing values with values drawn from the dataset’s empirical distribution which
in addition is to be scaled and shifted. While scaling is said to prevent the imputed
values from having high weight in the subsequent statistical evaluation, down-shifting is
motivated by the fact that low-expression proteins are more likely to remain undetected
and thus lead to zero measured counts.
Since there are typically many missing values that need to be imputed, it is not
surprising that their imputation has the potential to dramatically change results of the
subsequent differential expression analysis. To demonstrate that, we apply imputation
with various values of the scale and shift parameters (see Imputation of missing values
for details) to the transcriptomic data which, as shown in Fig 1, are free of irregular
zeros and hence the results obtained with usual tools can be considered as reliable. In
particular, we compare the significant genes identified by the edgeR package [2] in the
original transcriptomic dataset with the significant genes identified by edgeR after all
missing values are imputed. Fig 2 shows that the impact of imputation is substantial:
Around 80% of the originally identified significantly changing genes are lost by the
recommended shift −1.8 and scale 0.5. While comparatively better results are obtained
with scale 0 and shift either −2 or 0 (the bottom left and right corners, respectively),
around 70% of the original significant genes are still lost. Of the two “favorable” settings,
we thus use imputation with zero shift and scale one from now on (i.e., the missing
values are replaced with the dataset’s mean). The other setting, shift −2 and 0, while
comparatively well-performing in this evaluation, is sensitive to irregular zeros (results
not shown).
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Robustness of differential expression analysis methods to irregu-
lar zeros
Having seen that the often-used imputation of missing values does not provide a definitive
answer to the problem of irregular zeros, our main contribution is to propose a ranking-
based approach to find significantly changing genes. By contrast to R’s RankProd
package [15,16], which is also based on ranking the genes by fold-change values, we rank
comparisons that involve a missing value separately from those that do not involve a
missing value (see ProtRank description for a detailed description). The need for a double
ranking is motivated by the fact that, as shown in Missing values in proteomic data and
their impact, it is impossible to rely on logarithmic fold changes when irregular zeros
are present. At the same time, the missing values are not necessarily a manifestation
of an erroneous or noisy measurement and can contain useful information: If a gene
goes from a positive value to zero consistently in multiple comparisons, this may be an
indication that the gene is downregulated in the comparison. We propose a method
that takes both cases into account: The logarithmic fold changes and their magnitude
relatively to other genes’ fold changes are computed for comparisons without missing
values, all comparisons where a zero count changes in a positive count are assigned the
same relatively high virtual rank, and all comparisons where a positive count changes in
a zero count are assigned the same relatively low rank. Since this method is rank-based
and aims in particular at proteomic and phosphoproteomic data where the missing values
problem is particularly common, we call the new method ProtRank.
To demonstrate the new method’s robustness with respect to irregular zeros, we
compare it with the behavior of edgeR which is probably the most popular tool for
differential expression analysis [2] that we use both with and without imputation of
missing values. We apply the methods on the transcriptomic dataset used in the previous
section which, as we have seen, is essentially free of irregular zeros. We introduce the
irregular zeros in the dataset by choosing at random a given fraction of positive values
in the original dataset and changing them in zeros; in this way, we obtain perturbed
datasets. We aim to study how does the noise in the particular form of zeros introduced
in the data at random influence each respective method: EdgeR without imputation,
edgeR with imputation, and the newly introduced ProtRank.
Since the original transcriptomic dataset is essentially free of irregular zeros, the
significant genes identified by edgeR in the original dataset provide a natural benchmark
against which results obtained with other methods can be compared; this set of original
significant differentially expressed (DE) genes is denoted O. We denote the set of
significant DE genes identified by method m in perturbed data as Pm and compare
it with the original set O. For this comparison, we use precision and recall which
are metrics commonly used in data mining literature [17, 18]. Precision is defined as
the fraction of the perturbed significant genes that are also original significant genes,
|Pm ∩ O|/|Pm|. Recall is defined as the fraction of originally identified significant genes
that are also among the perturbed DE genes, |Pm ∩ O|/|O|. Both metrics range from 0
(worst result) to 1 (best result). We use the described approach to evaluate the original
edgeR package, edgeR with imputation, and the newly developed ProtRank method. In
each case, we use the false discovery rate (FDR) threshold of 0.20 to decide whether a
gene is significant or not. To make the impact of irregular zeros explicit, we also assess
the fraction of zero counts corresponding to the identified significant DE genes.
Fig 3 summarizes the results of the robustness analysis. EdgeR without imputation
naturally obtains the perfect result on unperturbed data (zero fraction of added zeros) as
the benchmark DE genes are also obtained with edgeR on unperturbed data. However,
its sensitivity to irregular zeros is high: When as few as 1% of positive counts are turned
into zeros, recall drops under 20% (i.e., more than 80% of the originally identified
significant genes are lost). The method’s precision decays slower but still much faster
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Fig 3. The impact of zeros added at random in the data. Precision (A) and recall (B) of various differential
expression analysis methods computed with respect to the significant DE genes identified by edgeR in the original data.
The fraction of zero counts among the identified DE genes (C) shows how much is each method influenced by the added
zeros. The error bars show the standard deviation values computed from the analysis of 10 independent perturbed sets
for each fraction of added zeros.
than is the case for the other methods. By contrast, edgeR with imputation is quite
resistant to additional irregular zeros as its precision and recall decrease by roughly
40% when as much as 10% of zeros are added in data at random. Albeit stable, the
results are quite bad with precision and recall decreasing from 0.31 to less than 0.20
(this is in agreement with Fig 2). ProtRank is even more robust to irregular zeros:
Its precision is stable and its recall decreases by roughly 40% similarly to edgeR with
imputation. The most important observation is that precision and recall achieved by
ProtRank are significantly better than that of edgeR with imputation in the whole range
of perturbation fractions. ProtRank outperforms edgeR without imputation in terms of
recall (which is the more important of the two metrics as it quantifies how many of the
originally found DE genes do we still find in the perturbed data) for all perturbation
fractions except for the two smallest ones.
The last panel shows that the significant genes chosen by ProtRank have the smallest
fraction of zero counts of the three methods. EdgeR without imputation is expectedly
sensitive to the introduced zeros and the chosen significant genes have more than 40% of
zero counts when as few as 1% of positive counts are changed in zeros. This shows that
the irregular zeros, that we introduce at random and without any relation to differential
expression of genes, chiefly determine which genes are chosen by edgeR as significantly
differentially expressed. While less sensitive to the fraction of added zeros itself, edgeR
with imputation also chooses significant genes with many zero counts (that are in turn
changed in positive values by imputation). This high starting value shows that the
imputation process itself, albeit assumed to solve the problem of missing values, biases
the selection of significantly DE genes towards the genes that have many missing values.
By contrast, ProtRank chooses significant genes with few zero counts and the fraction of
zero counts increases slowly with the fraction of added zeros.
To better understand the difference between the results produced by the three
considered methods, we evaluate the positions of the DE genes identified by edgeR in the
other two rankings: The ranking produced by edgeR with imputation and the ranking
produced by ProtRank (in the rankings, the genes are ranked by the significance of their
differential expression from the most to the least significant). In Fig 4, we visualize the
comparison using the well-known receiver operating characteristic (ROC) curve [19, 20]
and the precision-recall (PR) curve that has been advocated for use in biological data
in [21]. The ROC curve in Fig 4A, in particular, the inset focusing at the top of the
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Fig 4. A comparison of the significant genes and rankings obtained with respective methods. (A) The
receiver operating characteristic (ROC) curves based on comparing with the DE genes identified by edgeR; the bottom-left
corner is magnified in the inset. (B) The precision-recall (PR) curves based on comparing with the DE genes identified by
edgeR. (C) The receiver operating characteristic (ROC) curves based on comparing with the DE genes identified by
ProtRank and edgeR with imputation, respectively, in the ranking of genes produced by edgeR on the original data.
rankings, show that the ProtRank’s ranking has the edgeR’s DE genes at higher positions
than edgeR with imputation does.
The reason why [21] suggest to use the PR curve instead of the ROC curve is that
the number of positive instances (in our case represented by the correctly identified
differentially expressed genes) is much smaller than the number of negative instances
(in our case represented by the genes that are correctly identified as not differentially
expressed). The ROC curve involves true negatives in its computation which, due to
their abundance, give rise ROC curves that have a large area under them; this area is
a common way to quantify a ROC curve. This is well visible in panel Fig 4A where
the areas under the two ROC curves are 0.98 and 0.87, respectively. The PR curves in
Fig 4B overcome this limitation and make a clear distinction between the two evaluated
methods: The area under the ProtRank’s PR curve, 0.45, is four times as large as the
area 0.11 produced by edgeR with imputation.
We finally do a reverse check and examine the positions of the significant DE genes
identified by edgeR with imputation and ProtRank, respectively, in the ranking of genes
by the significance of their differential expression produced by edgeR. The result is shown
in Fig 4 where it is immediately visible that the significant genes chosen by ProtRank
are all highly ranked in the original gene ranking produced by edgeR without imputation.
In fact, all ProtRank’s significant genes (we use the FDR threshold of 0.20 again) are in
the top 2.2% of the ranking of genes by edgeR in the unperturbed data. By contrast, a
substantial fraction of genes chosen by edgeR with imputation are scattered through
the lower parts of the original gene ranking. This shows that in the absence of irregular
zeros, results obtained with ProtRank are similar to those obtained with edgeR without
imputation of missing values.
Results on the phosphoproteomic data
We now return to the phoshoproteomic data that initially motivated the development
of the statistical framework that we introduce in this paper (see Description of the
phosphoproteomic data for a detailed dataset description). Since the complete anal-
ysis of the data, supplemented by extensive biological experiments, will be part of a
forthcoming manuscript [Koch et al, manuscript in preparation], we provide here only a
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general evaluation of the identified significantly differentially expressed phosphopeptides.
Without the loss of generality, we use the data corresponding to four samples measured
one hour after irradiation (SAMT IR1h 1, SAMT IR1h 2, SAYH IR1h 1, SAYH IR1h 2)
and four corresponding controls (SAMT C 1, SAMT C 2, SAYH C 1, SAYH C 2). As
explained in Description of the phosphoproteomic data, SA, MT, and YH are three
respective mutations that the sample cells can have; labels 1 and 2 mark two biological
duplicates that were available for each mutation combination. In the measurement data,
there are 6201 peptides that have at least one positive count in the eight aforementioned
samples. The dataset contains 31% of zero counts, many of which are irregular zeros
(i.e., they correspond to a pair of samples where the given phosphopeptide’s count in
the other sample is larger than the median count).
The numbers of DE phosphopeptides identified by respective approaches using
the FDR threshold 0.20 are: 1278 for edgeR without imputation, 93 for edgeR with
imputation, and 45 for ProtRank. The result obtained with edgeR without imputation
is clearly excessive with more than 20% of all peptides being identified as significantly
differentially expressed. This is due to the irregular zeros that distort the results; this is
shown by 63% of the DE phosphopeptides’ counts being zeros, which is more than double
of the overall fraction of zero counts in the data. EdgeR with imputation does not have a
similar problem and yields a similar number of differentially expressed phosphopeptides
as ProtRank.
To gain further insights, we evaluate median counts (computed from the positive
counts only) of the identified DE phosphopeptides, in particular in comparison with
median counts of all phosphopeptides. Denoting the fraction of the identified DE
phosphopeptides in the count bin b as fDEb and the fraction of all phosphopeptides
in the count bin b as f0b , the ratio f
DE
b /f
0
b quantifies the relative representation of
DE phosphopeptides from the given count bin b. When the relative representation
is more than one, the given count bin b is over-represented among the identified DE
phosphopeptides. When the relative representation is less than one, the given count bin
b is under-represented among the identified DE phosphopeptides.
The result is shown in Fig 5 which shows that the three evaluated approaches greatly
differ in how their representation changes with the median phosphopeptide count. While
edgeR without imputation and ProtRank show little bias over the whole range of median
counts, edgeR with imputation shows a strong bias against phosphopeptides whose
counts are close to the overall average count. EdgeR’s behavior is a direct consequence
of the imputation process that replaces missing values with mean count (in our case)
and thus makes it possible that the phosphopeptides with low or high median count
can have high apparent changes between their low/high actual counts and the average
counts introduced by imputation. This is well visible in Fig 5 where bins close to the
average count are strongly under-represented, and bins containing phosphopeptides with
low/high counts are over-represented.
To summarize the results obtained on the phosphoproteomic data: ProtRank yields a
plausible number of DE phosphopeptides which furthermore show no systemic biases. By
contrast, edgeR without imputation produces an excess number of DE phosphopeptides
and edgeR with imputation is strongly skewed toward phosphopeptides that have either
low or high counts.
The complex experimental setup of this dataset allows us to illustrate another
ProtRank’s asset: The possibility to simultaneously address all possible differential
expression patterns (see ProtRank description for details). In the case of the given
dataset, for example, it is possible that the two types of samples (SAMT and SAYH) react
to irradiation in a different way: Some phosphopeptides can increase upon irradiation in
SAMT samples and decrease upon irradiation in SAYH samples, for example. Besides the
baseline comparison of all irradiated samples with their counterpart controls, ProtRank
October 1, 2019 8/18
13 14 15 16 17
ln(median nonzero count)
0
1
2
3
4
re
pr
es
en
ta
tio
n
edgeR without imputation
edgeR with imputation
ProtRank
Fig 5. The relative representation of DE phosphopeptides identified by
various methods as a function of their log-transformed median count. The
representation value of one indicates that phosphopeptides with the given median count
are neither over-represented nor under-represented among the identified DE
phosphopeptides.
makes it possible to consider two separate groups—SAMT samples and SAYH samples,
in this case. The rank score of each gene is then computed in such a way that the genes
that consistently increase upon irradiation in both SAMT and SAYH samples, the genes
that consistently decrease upon irradiation in both SAMT and SAYH samples, as well as
the genes that increase upon irradiation in SAMT and decrease in SAYH samples (and
vice versa), are assigned a high rank score. From the 45 genes identified by ProtRank
as differentially expressed, 18 increase upon irradiation in both SAMT and SAYH, 18
decrease in both SAMT and SAYH, 6 increase in SAMT and decrease in SAYH, and 3
decrease in SAMT and increase in SAYH. The increase in SAMT and decrease in SAYH
combination produces a particularly robust signal with two of the identified genes having
FDR < 0.01.
Similar multi-directional analyses are also possible using other tools—such as edgeR
that we use here for comparison—but they need to be manually done separately for each
combination of directions, and the obtained results have to be compiled whilst explicitly
taking into account that they come from multiple comparisons. ProtRank allows the
same analysis to be carried out in two lines (first defining the groups of comparisons to
be made, second calling ProtRank’s main gene-ranking function).
Comparison with Perseus and Proteus
We have shown so far that ProtRank overcomes the problem of missing values without
the need to impute them and, at the same time, produces results that are in the
absence of irregular zeros to a large extent comparable with results produced by the
state-of-art differential analysis tool edgeR [2]. We now proceed by briefly comparing
the ProtRank results with the results obtained by two other existing tools: (1) Perseus,
a well-established computational platform for proteomic data [7] which uses imputation
to deal with missing values and (2) Proteus, a recent R package for the analysis of
quantitative proteomics data [22]. As we further argue in Discussion, a comprehensive
comparison of the available tools should also include the use of synthetic datasets
benchmarked against a number of different real datasets. We see this as an important
task for future research.
With Perseus, we used the transcriptomics dataset which, as we have seen, is essentially
free of irregular zeros and EdgeR is therefore expected to produce a meaningful differential
expression analysis result. We first log-transformed the counts and then imputed the
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missing values [7]. While the software offers two different imputation approaches, the
default imputation based on the mean and the standard deviation for each sample
and the “global” imputation based on the mean and the standard deviation for all
samples, the results are qualitatively similar for both of them. We used the function
“multiple-sample test” to identify the genes that are differentially expressed between
the primary and recurrent tumor samples. Despite trying various analysis settings,
Perseus identifies a small number of genes as differentially expressed. We thus focus
our comparison on the top 100 most differentially expressed genes, even when they are
not marked as significant. Of them, less than 10% are among the 114 significantly DE
genes identified by edgeR. The area under the precision-recall curve is 0.04 as opposed
to 0.45 achieved by ProtRank. In other words, the ranking of genes produced by Perseus
substantially differs from the ranking of genes produced by edgeR. This is in line with
our previous observation that imputation has the potential to dramatically alter the
differential expression analysis results. By changing a chosen fraction of counts to zeros,
we can further probe the Perseus’s robustness with respect to artificially introduced
zeros. When 0.02 of all counts are chosen at random and changed to zeros, 40% of the
original top 100 genes remain in the top 100 on average. When the fraction of zeros
introduced at random increases to 0.10, 25% of the original top 100 genes remain in the
top 100 on average. These results are similar to those achieved by ProtRank.
Proteus is designed to use an evidence file from MaxQuant as input and currently
lacks the possibility to use a simple table of peptide intensities instead; to apply Proteus
on the datasets studied here so far is therefore not possible. Instead, we use the peptide
intensities produced by the example described in [22] in Section 2.1. This dataset
contains data on 34,733 peptides measured in two biological conditions, named A and B,
and seven replicates each (14 samples in total). The dataset has the properties expected
for a mass spectrometry proteomics measurement: 26% of all counts are zeros and 6.5%
of all A vs. B comparisons involve irregular zeros. EdgeR is not expected to produce
high quality results for such input data. Proteus and ProtRank yield similar numbers of
significant DE peptides, 317 and 344, respectively, for the significance threshold of 0.05,
for example. The overlap between these two sets of DE peptides is 120 with further
100 peptides in each set identified as DE by the other tool at the significance level of
0.20. Similar findings follow on the aggregated protein intensities data obtained with
the Proteus’s function makeProteinTable (the resulting dataset contains 3525 proteins).
Proteus and ProtRank then yield 42 and 76 significant DE proteins, respectively, at the
significance threshold of 0.05, and the overlap of these two sets is 29. The conclusion is
that the DE analysis results obtained with Proteus and ProtRank are similar.
Discussion
We have shown that the presence of irregular zeros—missing values that in the differential
expression (DE) analysis occur in comparisons with substantial measured values—in
proteomics data importantly influences the resulting lists of DE genes produced by
common statistical tools such as edgeR. We stress that for other kinds of input data,
such as transcriptomics data, edgeR is a good statistical tool that produces high-quality
results.
There are two main directions that we see for the future development of ProtRank.
Firstly, the computationally intensive bootstrap step (which is used to estimate the false
detection rate, FDR) could be replaced by an approximate analytical procedure. The
first motivation for such an approach is provided by Fig 7 where the aggregate bootstrap
scores decay exponentially at the top positions of the gene ranking. Analytical estimates
of the bootstrap score distribution could then be used as a replacement for the actual
bootstrap procedure.
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Secondly, a different recent method, Proteus, addressing the problem of missing
values in proteomics [22] came to our attention in the final stages of this manuscript’s
preparation. We have shown in Comparison with Perseus and Proteus that albeit
similar, the results produced by ProtRank and Proteus differ in the evaluation of
numerous peptides and proteins. A detailed comparison of these methods on various
proteomic and phosphoproteomic datasets as done, for example, in [13] for methods
designed for transcriptomic data, is the natural first step. The natural limitation of
such a comparison is that the ground truth (the “correct” list of differentially expressed
peptides or phosphopeptides) is not known. This can be alleviated by evaluating the
methods also on synthetic datasets. Upon careful calibration, synthetic datasets can
share many of real datasets’ features which makes the subsequent evaluation of methods
more credible [23]. Combined benchmarking of methods on real and synthetic datasets
could help establish a comprehensive robust statistical framework for the analysis of
proteomic data.
Conclusions
We propose here a novel method for differential expression analysis of proteomic and
phosphoproteomic data. The main advantage of this new method is that it is robust to
the missing values that are common for proteomic and phosphoproteomic measurements.
As a result, it does not require the imputation step which is commonly used to eliminate
the missing values [7], yet we show here that it at the same time importantly affects
the obtained results. In data where missing values are absent, the new method—which
we refer to as ProtRank because it is based on rankings—produces similar results as
edgeR which is a widely-used method for differential expression analysis. When missing
values are artificially introduced in the data, ProtRank’s results are more stable than
the results produced by edgeR which is a demonstration of ProtRank’s robustness to
missing values.
ProtRank requires no parameters to be fine-tuned for the analysis. It also does not
employ any normalization of counts in individual samples as this would not change the
gene ranking that is taken into account by the method (only the numeric fold change
values would change upon normalization). Importantly, ProtRank makes it possible to
automatically address more complex differential expression patterns such as the case
discussed in Results on the phosphoproteomic data where irradiation was applied on
samples with various mutations and it was, in principle, possible that samples with
one mutation react to irradiation differently than samples with other mutations. An
implementation of ProtRank is available at https://github.com/8medom/ProtRank as
an easy to use Python package.
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Methods
Description of the transcriptomic data The transcriptomic data from head and
neck squamous cell carcinoma patients have been originally analyzed in [14] (the authors
have used edgeR for the differential expression analysis). Out of the 15 cell lines used
in that study, we keep eight of them for pairwise differential expression analysis: Cell
lines UM-SCC-11A, -14A, -74A, and -81A from primary tumors, and cell lines UM-SCC-
11B, -14B, -74B, and -81B from recurrent tumors. This corresponds to four pairwise
comparisons (recurrent vs. primary) in total. Each sample has been measured once with
RNA sequencing which produced integer counts of 18,369 distinct transcripts (see [14]
for details of the experimental setup). In the data, 11.9% of all counts are zero and the
median of positive counts is 932. The fraction of pairwise comparisons where one count
is greater than this median and the other count is zero, is less than 0.01% (3 comparisons
out of 35,359); irregular zeros are thus essentially absent in this dataset.
Description of the phosphoproteomic data NIH3T3 mouse embryonic fibroblasts
were transfected with either the wild-type or one of five mutated forms (M1268T, Y1248H,
S1014A, M1268T/S1014A, Y1248H/S1914A) of the MET receptor tyrosine kinase were
irradiated with a single dose of 10 Gy (Gammacell GC40, MDS Nordion, Ontario,
Canada). Samples from the six cell lines have been subjected to phosphoproteomic
analysis via non-targeted mass spectrometry before irradiation, 1 hour after irradiation,
and 7 hours after irradiation. Since two biological duplicates of each of the cell lines have
been analyzed, the phosphoproteomic results are available for 6× 3× 2 = 36 samples in
total. Integer peptide counts of 7,572 unique peptides are available for each sample. In
the data, 43.6% of all counts are zero and the median of positive counts is 1, 294, 600.
The fraction of pairwise comparisons where one count is greater than this median, yet
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the other count is zero is 10.8%; irregular zeros are frequent in this dataset. An in-depth
analysis of this dataset will be presented in [Koch et al, manuscript in preparation].
Phosphoproteomic data experimental setup Cell cultures were washed, scraped
in phosphate-buffered saline and spun down for 5 minutes at 1000 rpm. Resulting pellets
were resuspended in 8 M urea solution containing 0.1 M ammonium bicarbonate and
disrupted by sonication. Supernatants were centrifuged at 12000 rpm for 10 minutes and
protein concentration was determined by BCA Protein Assay (Pierce). Disulfide bonds
were reduced with tris(2-carboxyethyl)phosphine at a final concentration of 5 mM at 37◦C
for 30 minutes and alkylation of free thiols was performed with 10 mM iodoacetamide at
room temperature for 30 minutes in the dark. The solution was subsequently diluted
with 0.1 M ammonium bicarbonate to a final concentration of 1.5 M urea and digestion
was performed overnight at 37◦C by sequencing-grade modified trypsin (Promega) at a
protein-to-enzyme ratio of 50 : 1. Acidification was performed by adding formic acid to a
final pH < 3 in order to stop protein digestion. Peptides were desalted on a C18 Sep-Pak
cartridge (Waters) and one-tenth of the resulting eluate was processed individually for
total proteome analysis. Phosphopeptides were enriched from 1 mg of initial peptide
mass with TiO2 as previously described [24]. For mass spectrometry analysis, samples
were resuspended in 20µl of 2% acetonitrile, 0.1% formic acid, and 1µl of each sample
was used for injections. LC-MS/MS analysis was performed with an Easy nLC 1000
system (Thermo) connected to an Orbitrap Elite mass spectrometer (Thermo) equipped
with a NanoFlex electrospray source. Peptides were separated on an Acclaim PepMap
RSLC C18 column (150 mm × 75µm, 2 um particle size, Thermo) using a gradient of
5–30% buffer B (98% acetonitrile, 2% water, 0.15% formic acid) over 180 minutes at a
flow rate of 300 nl/min. The Orbitrap Elite was operated in data-dependent acquisition
mode, each cycle consisting of one MS scan followed by 15 MS/MS scans of the most
abundant precursor ions. Collision-induced dissociation was performed with the following
settings: Isolation width, 2 m/z; normalized collision energy, 35; activation time, 10 ms.
Acquired MS data files were subsequently processed for identification and quantification
using Maxquant version 1.5.2.8 [25]. Settings were kept as default with the following
specifications: ’First search peptide tolerance’ was set to 50 ppm and ’Main search
peptide tolerance’ to 10 ppm. The considered modifications were oxidation (Met) and
phosphorylation (Ser/Thr/Tyr). ’Label free quantification’ and ’Match between runs’
were enabled, with a match time window of two minutes. The search was performed
against the mouse UniProt FASTA dataset UP000000589.
Imputation of missing values As can be seen in Fig 6, the bulk of the distribution
of the logarithm of positive gene counts can be well fitted with the normal distribution
with mean µ0 = 7.7 and standard deviation σ0 = 1.3. In line with [7], we thus replace
the missing values with exp(V ) where V is drawn from the normal distribution with
mean 7.7 + δσ0 and standard deviation λσ0. The exponential transformation is needed
here to go from the logarithmic counts used for display in Fig 6 back to the natural
range and scale of gene counts. Parameters δ and λ are referred to as shift and scale,
respectively. While [7] recommends the choice δ = −1.8 and λ = 0.5, the investigation
of the parameter space in Fig 2 suggests δ = 0, λ = 0 to be a better choice when
imputed data are used as input for the edgeR package and analyzed using its functions
calcNormFactors, EstimateDisp, glmFit, and glmLRT.
ProtRank description Counts ng,i of all genes (g = 1, . . . , G; we use “gene” here as
a generic term here) in all samples (i = 1, . . . , S) serve as input data for the analysis. The
samples are organized in C = S/2 pairwise comparisons (c = 1, . . . , C) that represent a
change of conditions (before and after treatment, typically) for a given system (a cell
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Fig 6. Distribution of the logarithm of the positive counts in the phoshoproteomic data
(solid line) and the normal distribution with µ0 = 7.7 and σ0 = 1.3 that fits the bulk of
the distribution.
line or a patient). The comparisons are further organized in groups of comparisons that
are expected to go in the same direction. In the analysis described in Results on the
phosphoproteomic data, one group of comparisons includes SAMT samples and the other
group of comparisons includes SAYH samples. If the change is expected to be in the
same direction in all samples (as would be the case when analyzing data from biological
or technical duplicates of a system), there is only one group including all analyzed
sample comparisons. The opposite extreme where each comparison forms a separate
group is also possible, but groups involving more comparisons (including duplicates
of the same conditions or comparisons of several samples that are expected to react
uniformly) are likely to produce better results. Denoting the set of all comparisons as
C, we can write C = {G1, . . . , GN} where N is the number of comparison groups. Then
for group Gn is composed of individual comparisons, Gn = {cn,1, . . . , cn,Mn} where Mn
is the number of comparisons in group n. Finally, comparison cn,j is composed of two
samples, cn,j = {sBn,j , sAn,j} which correspond to the sample before and after treatment,
respectively.
We first consider a single comparison of samples sBn,j and s
A
n,j . For all genes g that
have been registered in both these samples, we denote their number as Ω(sBn,j , s
A
n,j), we
compute their logarithmic fold change values
xg(s
B
n,j → sAn,j) = log2
ng,sAn,j + n0
ng,sBn,j + n0
(2)
and consequently compute their rank rg(s
B
n,j → sAn,j) by the logarithmic fold change
from the highest (ranked 1) to the lowest [ranked Ω(sBn,j , s
A
n,j)]. This rank is further
rescaled to the rank score
σg(s
B
n,j → sAn,j) =
rg(s
B
n,j → sAn,j)− 0.5
Ω(sBn,j , s
A
n,j)
(3)
which, thanks to the shift by 0.5, is symmetrically distributed in the range [0, 1] (the
lowest rank score is as far from zero as the highest is from one). The rank score σ is the
basis of ProtRank’s gene ranking.
Before proceeding, we have to assign a rank score to the genes that have zero counts
in either (or both) of the compared samples. Since the change from a zero count to a
positive count corresponds to a large positive logarithmic fold change, we assign those
pairs uniform rank score σ0 which is the method’s parameter. We set σ0 = 0.1 which
corresponds to assigning the change from zero to a positive count the same score as
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Fig 7. The rank plot of the gene rank score computed by ProtRank in the
transcriptomic data (real and bootstrapped data). The shaded region indicates the
standard deviation in bootstrap realizations. At the FDR threshold of 0.20, ProtRank
finds 116 significant DE genes. In the bootstrap data, there are 23 genes that have a
better averafe score than the 116th gene in the real data (23/116 ≈ 0.198).
assigned to a pair of two positive counts with the 10th percentile logarithmic fold change.
In general, lower values of σ0 result in a higher fraction of zero counts among the
identified differentially expressed genes. The precise choice of σ0 is made less important
by Eq. (4) which log-transforms the computed scores. Analogously, the change form
a positive count to zero corresponds to a large negative logarithmic fold change. We
assign those pairs with score 1− σ0 which is the same as the score assigned to a pair of
two positive counts with the 90th percentile logarithmic fold change. Finally, pairs with
two zero counts are ignored in the computation of the final score because they provide
no useful information for the differential expression analysis.
To rank the genes based on all comparisons, we now have to aggregate individual
rank scores into a final rank score. Similarly to [15, 16], this is done by multiplying the
logarithm of individual rank scores from all comparison groups as
N∏
n=1
Mn∏
j=1
[− lnσg(sBn,j → sAn,j)]. (4)
Terms corresponding to comparisons involving two zero counts are ignored from the
aggregation process. To understand why the logarithmic transformation here is preferable
to directly multiplying individual rank scores, consider the case where a gene has the
largest positive logarithmic fold change of all in one comparison and the largest negative
logarithmic fold change in another one. Assuming that there are, for example, N = 5000
genes in total, the respective rank scores are 0.5/N = 10−4 and 1− 0.5/N = 1− 10−4,
respectively. Their direct multiplication then yields approximately 10−4 which is the
same values as a gene whose logarithmic fold change is 50th largest in both cases
(both individual rank scores would then be approximately 10−2). This is obviously an
undesired outcome as the two mentioned genes are far from being similarly differentially
expressed. The problem is overcome by aggregating according to Eq. (4): The first gene
then scores 9.21 × 10−4 ≈ 10−3 which is far less than the second gene whose score is
4.6 × 4.6 ≈ 21.2. In other words, Eq. (4) favors the genes whose expression changes
similarly in all comparisons at the cost of genes whose expression changes wildly in
different directions.
Given the final score obtained with Eq. (4), genes with the highest final rank score
are candidates for differentially expressed genes. However, this would seek only for genes
with small rank score (that is, large positive logarithmic fold change) in all comparisons.
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To achieve our goal of allowing to search for genes with different direction of change in
respective comparison groups, we introduce the set of group directions D = {d1, . . . , dN},
where dn = −1 corresponds to searching for genes with large negative logarithmic fold
change in group n (i.e., high rank score σ) and dn = 1 corresponds to searching for
genes with large positive logarithmic fold change in group n (i.e., low rank rank score σ).
The final rank score is then computed as the minimal rank achieved out of all possible
group directions,
σg = minD
N∏
n=1
Mn∏
j=1
[
− ln
(1
2
− dn
2
+ dn σg(s
B
n,j → sAn,j)
)]
, (5)
where the inner-most term simplifies to σg(s
B
n,j → sAn,j) when dn = 1 (seeking for genes
upregulated in group n) and to 1 − σg(sBn,j → sAn,j) when dn = −1 (seeking for genes
downregulated in group n). Terms corresponding to comparisons involving two zero
counts are again ignored from computing the aggregate score. Genes are then ranked by
their final rank score from the highest to the lowest.
To decide which genes are significantly differentially expressed in the data, we use
nonparametric bootstrap [26,27]: We create simulated score tables by randomizing the
gene rank scores for each individual comparison. The original final rank scores of the
genes are then compared with their final rank scores in bootstrap realizations. This
allows us to determine which rank scores in the original data are perhaps small but still
likely to occur by chance, and which are so small that they correspond to differentially
expressed genes (see Fig 7 for an illustration). Now take gene g that is ranked rg by
Eq. (5); the most differentially expressed gene has rank 1. In each bootstrap realization,
we compute the number of genes whose final rank score is better than the real final rank
score of gene g, and compute their average number Ng over all realizations. The false
discovery rate for gene g is then estimated as Ng/rg. As one proceeds down the ranking,
the quantity Ng/rg can sometimes decrease. In such a case, we assign the gene with
the false discovery rate estimated for the previous better-ranked gene. This forces the
estimated false discovery rate to increase monotonously.
How to use the ProtRank package A Python implementation of the new method
can be downloaded from https://github.com/8medom/ProtRank. The github reposi-
tory contains the package file ProtRank.py as well as the synthetic dataset sample_dataset.dat
and the Python script sample_dataset_analysis.py which provides a simple example
of how to use the ProtRank package.
The elementary package usage comprises two steps: loading the data for analysis
using load_data function and carrying out the differential expression analysis using
rank_proteins function. To analyze the aforementioned synthetic dataset, the minimal
example is:
import ProtRank
what_to_compare = [[[’A1’, ’B1’], [’A2’, ’B2’], [’A3’, ’B3’], [’A4’, ’B4’]]]
description = ’A_vs_B ’
dataset = ProtRank.load_data(’sample_dataset.dat’)
significant = ProtRank.rank_proteins(dataset , what_to_compare , description)
Variable significant stores the list of the identified differentially expressed proteins
(identified by the index of the corresponding rows).
In addition, basic statistical properties of the dataset can be displayed using data_stats
function, and the logarithmic fold changes computed for selected rows (typically those
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corresponding to the identified differentially expressed genes; we can use the list
significant created by the code above, for example) can be visualized using plot_lfc
function.
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